OBJECTIVE: Interleukin (IL)-33 is involved in the development of lung inflammation by inducing or amplifying Th2 type-mediated responses in various animal models of allergic asthma. The ST2 gene is a member of the IL-1 receptor family, producing a transmembrane form (ST2L) and a soluble secreted form (sST2). sST2 has been shown to block this IL-33/ST2 signaling pathway. This study aimed to investigate whether anti-IL-33 and sST2 reduced airway inflammation in a murine model of asthma. METHODS: BALB/c mice were sensitized and challenged with ovalbumin (OVA), and the effect of sST2 and anti-IL-33 antibody on airway inflammation and airway hyperresponsiveness (AHR) was evaluated. Furthermore, we measured changes in various cytokines in the bronchoalveolar lavage (BAL) fluid when treated with sST2 or anti-IL-33. RESULTS: We observed that anti-IL-33 antibody and sST2 exert a negative regulation on OVA-mediated allergic airway inflammation. Both treatments reduced total cell counts and eosinophil counts in BAL fluid and AHR to methacholine. The Th2 cytokines, such as IL-4, IL-5, and IL-13 in BAL fluid were also significantly decreased after both treatments. However, there were no changes in the level of TGF- ß1 and IL-10 after each treatment. CONCLUSIONS: These results suggest that anti-IL-33 as well as sST2 have therapeutic potential for allergic asthma through inhibition of Th2 cytokine production.
OBJECTIVE: Interleukin (IL)-33 is involved in the development of lung inflammation by inducing or amplifying Th2 type-mediated responses in various animal models of allergic asthma. The ST2 gene is a member of the IL-1 receptor family, producing a transmembrane form (ST2L) and a soluble secreted form (sST2). sST2 has been shown to block this IL-33/ST2 signaling pathway. This study aimed to investigate whether anti-IL-33 and sST2 reduced airway inflammation in a murine model of asthma. METHODS: BALB/c mice were sensitized and challenged with ovalbumin (OVA), and the effect of sST2 and anti-IL-33 antibody on airway inflammation and airway hyperresponsiveness (AHR) was evaluated. Furthermore, we measured changes in various cytokines in the bronchoalveolar lavage (BAL) fluid when treated with sST2 or anti-IL-33. RESULTS: We observed that anti-IL-33 antibody and sST2 exert a negative regulation on OVA-mediated allergic airway inflammation. Both treatments reduced total cell counts and eosinophil counts in BAL fluid and AHR to methacholine. The Th2 cytokines, such as IL-4, IL-5, and IL-13 in BAL fluid were also significantly decreased after both treatments. However, there were no changes in the level of TGF- ß1 and IL-10 after each treatment. CONCLUSIONS: These results suggest that anti-IL-33 as well as sST2 have therapeutic potential for allergic asthma through inhibition of Th2 cytokine production.
Authors: Jenna M Magat; Joanna L Thomas; Justin P Dumouchel; Fiona Murray; Willis X Li; Jinghong Li Journal: J Immunol Date: 2020-01-27 Impact factor: 5.422
Authors: Heather L Caslin; Jamie Josephine Avila McLeod; Andrew J Spence; Amina Abdul Qayum; Elizabeth Motunrayo Kolawole; Marcela T Taruselli; Anuya Paranjape; Howard L Elford; John J Ryan Journal: Cell Immunol Date: 2017-07-11 Impact factor: 4.868
Authors: Ayse Bilge Ozturk; Benjamin Arthur Turturice; David L Perkins; Patricia W Finn Journal: Curr Allergy Asthma Rep Date: 2017-08-10 Impact factor: 4.806
Authors: Jared Travers; Mark Rochman; Cora E Miracle; Jared P Cohen; Marc E Rothenberg Journal: J Allergy Clin Immunol Date: 2016-09-21 Impact factor: 10.793
Authors: Erin D Gordon; Joe Palandra; Agata Wesolowska-Andersen; Lando Ringel; Cydney L Rios; Marrah E Lachowicz-Scroggins; Louis Z Sharp; Jamie L Everman; Hannah J MacLeod; Jae W Lee; Robert J Mason; Michael A Matthay; Richard T Sheldon; Michael C Peters; Karl H Nocka; John V Fahy; Max A Seibold Journal: JCI Insight Date: 2016-09-08